Skip to main content

Advertisement

Table 2 Tumour uptake of 89Zr-RG7356 and RG7356 at 96 h p.i.

From: Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody

Patient Dose cohort (mg) Visual assessment Localisation SUVpeak AUC (mg h/mL) Tumour-to-blood AUC ratio
1 1
2 100
3 100 *
4 100
5 200
6 200
7 450 + Brain L 1.8 0.35 0.09
Lung R 8.4 2.06 0.55
8 450 + Skull L 3.3 1.41 0.43
Upper neck L 3.5 1.62 0.49
Lower neck L 2.8 1.43 0.43
Supraclavicular R 3.1 1.67 0.50
Mediastinal 4.8 2.37 0.72
Lung L 2.2 1.29 0.39
Lung R1 2.1 1.06 0.32
Lung R2 4.3 1.75 0.53
9 450 + Lung L 1.8 0.89 0.32
Lung R 2.2 0.99 0.36
Rectum 5.6 1.75 0.64
10 450 + Lung L 4.6 1.47 0.56
Lung R 3.9 1.41 0.53
11 450 + Mastoid L 4.5 1.81 0.42
12 675 + Sigmoid L 4.9 2.55 0.59
13 675 + Pelvic R 6.5 3.83 0.73
Sacrum 8.1 3.29 0.63
  1. no visible tumour uptake
  2. *Diffuse uptake in the lung